Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Finally, the stock now looks reasonably valued, especially given significant clinical and commercial catalysts on the horizon ...

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market ...

The Danish anti-obesity drugmaker slashed prices for its Wegovy and Ozempic treatments. Shares fell more than 1%. ↘️ [XPeng ...

Novo Nordisk has started selling its weight-loss drug Wegovy for $349 a month to cash payers, implementing the price cut months earlier than planned under its agr ...

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Investing.com -- Novo Nordisk ’s CEO Mike Doustdar said Monday that the company’s agreement with the White House to reduce prices on its popular weight-loss drugs is designed to expand access through ...

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 ...